馬偕醫學大學機構典藏(MacKay Medical University Institutional Repository):Item 987654321/2797
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 1657/1756
Visitors : 3729162      Online Users : 180
RC Version 5.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Adv. Search
LoginUploadHelpAboutAdminister
MMUIR > College of Medicine > Department of Optometry > Journal >  Item 987654321/2797

Please use this identifier to cite or link to this item: http://140.112.115.32:8080/ir/handle/987654321/2797

Title: Embelin as a novel inhibitor of PKC in the prevention of platelet activation and thrombus formation
Authors: Li, Jiun Yi;Chen, Ray Jade;Huang, Li Ting;Lee, Tzu Yin;Lu, Wan Jung;Lin, Kuan Hung
Contributors: 視光學系
Keywords: embelin;granule release;platelet aggregation;PKC;thrombus formation
Date: 2019-10-01
Issue Date: 2025-08-11 14:44:02 (UTC+8)
Abstract: Embelin is a quinone derivative and found in the fruits of Embelia ribes Burm.f. Embelin has been identified as a small molecular inhibitor of X-chromosome-linked inhibitor of apoptosis proteins, and has multiple biological activities, including antioxidation, anti-inflammation, and antitumor effects. However, the effect of embelin in platelets remains unclear. Thus, this study investigated the antiplatelet mechanism of embelin. Our data revealed that embelin could inhibit platelet aggregation induced by various agonists, including the protein kinase C (PKC) activator phorbol 12,13-dibutyrate (PDBu). Embelin, as well as the PKC inhibitor Ro 31-8220, markedly reduced PDBu-mediated phosphorylation of the PKC substrate, suggesting that embelin may be a PKC inhibitor for platelets. Embelin could block PKC downstream signaling and events, including the inhibition of protein kinase B and mitogen-activated protein kinase activation, granule release, and glycoprotein IIbIIIa activation. Moreover, embelin could delay thrombus formation in the mesenteric microvessels of mice, but did not significantly affect the tail bleeding time. In conclusion, we demonstrated that embelin is a PKC inhibitor and possesses antiplatelet and antithrombotic effects. The further analysis is necessary to more accurately determine clinical therapeutic potential of embelin in all clinical thromboembolic events with disturbance of thrombocyte function.
Relation: Journal of Clinical Medicine, 8(10). https://doi.org/10.3390/jcm8101724
Appears in Collections:[Department of Optometry] Journal

Files in This Item:

File SizeFormat
index.html0KbHTML1View/Open


All items in MMUIR are protected by copyright, with all rights reserved.

 


DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback